- The USPTO issues a Notice of Allowance (NOA) for Horizon Pharma's (NASDAQ:HZNP) patent application number 13/665,790 titled, "Treatment of Pain with Topical Diclofenac" which covers PENNSAID (diclofenac sodium topical solution) 2%.
- The U.S. patent, when issued, will be effective until July 10, 2029. It is the eleventh patent covering PENNSAID.
Horizon Pharma receives NOA for patent app covering PENNSAID
Recommended For You
More Trending News
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
HZNP | - | - |
Horizon Therapeutics Public Limited Company |